Capricor Therapeutics (NASDAQ:CAPR) Price Target Raised to $30.00 at Cantor Fitzgerald
Capricor Therapeutics (NASDAQ:CAPR – Free Report) had its price target raised by Cantor Fitzgerald from $25.00 to $30.00 in a research report released on Thursday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock. Other equities research analysts have also recently issued reports about the stock. HC Wainwright reiterated a “buy” […]
More Stories
Top 10 Investment Accounting Software & Other Related Software
Managing complex investment portfolios can be hectic most of the time, as a small mistake can lead to a huge...
Top 10 Richest K-Pop Idols in 2026
Do you also like K-pop or Korean pop? Then this article is for you. Let’s start. In this blog, you...
Over-the-Counter Medicines, Other Items Recalled Over Feces Contamination: FDA
By Jack Phillips The U.S. Food and Drug Administration (FDA) late last week announced that a distributor is recalling its...
Iranian President Says His Country in ‘Full-Fledged War’ With US, Europe, and Israel
By Jack Phillips Iranian President Masoud Pezeshkian said Saturday that the Iranian regime is in a full-scale war with the...
US Airline Industry Caps a Strong 2025—What Lies Ahead in 2026
By Panos Mourdoukoutas Despite a shaky start earlier in the year, U.S. airline travel reached another milestone during the 2025...
What Trump’s National Security Strategy Means for Canada
By Noe Chartier Canada receives but a passing mention in the recently released U.S. National Security Strategy, but that doesn’t...